Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Viavi Solutions Inc. Common Stock (VIAV) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

VIAVI Solutions (VIAV) trades at $41.28, down 1.13% on the day, with mixed technical signals showing bearish overall momentum but bullish moving averages. The company demonstrates strong revenue growth with fiscal 2026 revenue reaching $1.52B (up 40% YoY) and has beaten earnings estimates for three consecutive quarters. Recent developments include a U.S. Army contract for defense testing and expanded partnerships in network validation, positioning VIAV for growth in AI data center and defense markets.

While analyst consensus remains strongly bullish with a $60.25 price target (78.95% buy ratings), investors face risks from negative net income margins (-2%) and elevated valuation metrics (P/S 6.24, EV/EBITDA 60.68). The stock's outlook depends on continued execution in high-growth segments and margin improvement to justify current valuations amid competitive pressures.